Mori M - Search Results

1

Significance of INHBA expression in human colorectal cancer.

Okano M, Yamamoto H, Ohkuma H, Kano Y, Kim H, Nishikawa S, Konno M, Kawamoto K, Haraguchi N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Sekimoto M, Doki Y, Mori M, Ishii H. Okano M, et al. Among authors: mori m. Oncol Rep. 2013 Dec;30(6):2903-8. doi: 10.3892/or.2013.2761. Epub 2013 Oct 1. Oncol Rep. 2013. PMID: 24085226

2

Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes.

Mimori K, Ueo H, Kuroki T, Shiraishi T, Creer S, Taylor S, Ishii H, Mori M. Mimori K, et al. Among authors: mori m. Oncol Rep. 2004 Jul;12(1):19-23. Oncol Rep. 2004. PMID: 15201953

3

Clinical significance of the loss of MATS1 mRNA expression in colorectal cancer.

Kosaka Y, Mimori K, Tanaka F, Inoue H, Watanabe M, Mori M. Kosaka Y, et al. Among authors: mori m. Int J Oncol. 2007 Aug;31(2):333-8. Int J Oncol. 2007. PMID: 17611689

4

Clinical significance of ApoE expression in human gastric cancer.

Sakashita K, Tanaka F, Zhang X, Mimori K, Kamohara Y, Inoue H, Sawada T, Hirakawa K, Mori M. Sakashita K, et al. Among authors: mori m. Oncol Rep. 2008 Dec;20(6):1313-9. Oncol Rep. 2008. PMID: 19020708

5

Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells.

Saiki Y, Ishimaru S, Mimori K, Takatsuno Y, Nagahara M, Ishii H, Yamada K, Mori M. Saiki Y, et al. Among authors: mori m. Ann Surg Oncol. 2009 Sep;16(9):2638-44. doi: 10.1245/s10434-009-0567-5. Epub 2009 Jun 25. Ann Surg Oncol. 2009. PMID: 19554373

6

Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance.

Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H, Mori M. Iwatsuki M, et al. Among authors: mori m. Int J Cancer. 2010 Apr 15;126(8):1828-1837. doi: 10.1002/ijc.24879. Int J Cancer. 2010. PMID: 19739118

7

RGS16 is a marker for prognosis in colorectal cancer.

Miyoshi N, Ishii H, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Among authors: mori m. Ann Surg Oncol. 2009 Dec;16(12):3507-14. doi: 10.1245/s10434-009-0690-3. Epub 2009 Sep 4. Ann Surg Oncol. 2009. PMID: 19760045

8

Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors.

Hirose H, Ishii H, Mimori K, Ohta D, Ohkuma M, Tsujii H, Saito T, Sekimoto M, Doki Y, Mori M. Hirose H, et al. Among authors: mori m. Oncol Rep. 2010 Jan;23(1):35-43. Oncol Rep. 2010. PMID: 19956862

9

TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.

Miyoshi N, Ishii H, Mimori K, Tanaka F, Hitora T, Tei M, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Among authors: mori m. Ann Surg Oncol. 2010 Apr;17(4):967-72. doi: 10.1245/s10434-009-0865-y. Epub 2009 Dec 22. Ann Surg Oncol. 2010. PMID: 20033322

10

SCRN1 is a novel marker for prognosis in colorectal cancer.

Miyoshi N, Ishii H, Mimori K, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Among authors: mori m. J Surg Oncol. 2010 Feb 1;101(2):156-9. doi: 10.1002/jso.21459. J Surg Oncol. 2010. PMID: 20039278

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,937 results

Search Page

Filters